Microba Life Sciences (ASX:MAP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Microba Life Sciences (ASX:MAP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
2026 Annual Report & Appendix 4E
Microba reports FY26 results with revenue down 5.8%, loss up 38.7%, core testing revenue up 92%, and targets cash flow break-even in 2027
2026 Appendix 4G
2026 Corporate Governance Statement
Change of Director's Interest Notice - Pasquale Rombola
Change of Director's Interest Notice - Prof Ian Frazer
Cleansing Notice
Notification regarding unquoted securities - MAP
Notification regarding unquoted securities - MAP
Application for quotation of securities - MAP
Notification regarding unquoted securities - MAP
Application for quotation of securities - MAP
Completion of Share Purchase Plan
Microba completes $5.41 million capital raising via Placement and Share Purchase Plan
Results of General Meeting
Microba signs multi-year SYNLAB agreement
Q4 FY26 Quarterly Investor Presentation & Webinar
Microba reports strong Q4 FY26 growth, new product launch, and announces Share Purchase Plan
Q4 FY26 Quarterly Activities Report & Appendix 4C
Microba reports 92% core testing revenue growth in FY26, new product launch on track, and $7m cost savings target
Change in substantial holding
Details of Q4 FY26 Quarterly Report, Appendix 4C & Webinar
Ceasing to be a substantial holder
Letter to Shareholders, Notice of EGM & Proxy Form
Change in substantial holding
Cleansing Notice
Letter to SPP Eligible Shareholders
Microba launches $1 million Share Purchase Plan at $0.05 per share with free options
Disclosure Document - Prospectus
Microba Life Sciences launches $6 million capital raise via SPP and Placement with shareholder approval pending
Application for quotation of securities - MAP
Reinstatement to Quotation
Microba Life Sciences reinstated to ASX quotation after capital raise announcement
Proposed issue of securities - MAP
Proposed issue of securities - MAP
Proposed issue of securities - MAP
Proposed issue of securities - MAP
Investor presentation - path to cashflow breakeven
Microba announces A$5 million equity raise to fund path to cashflow break-even by 2027 amid strong diagnostics growth and therapeutics partnering
$5M secured to deliver cashflow breakeven and testing growth
Microba raises $5 million to fund growth and achieve cashflow break-even by 2027
Extension of Voluntary Suspension